Effect of bromocriptine on anthropometric, metabolic and inflammatory parameters in obese women

الملخص EN

Background: Obesity associated with high risk of cardiovascular disease and diabetes due to impairment in glucose and lipid metabolism as well as low grade inflammatory response.

Hypothalamic hypodopaminergic state is observed in obese subject.

Accordingly, treatment with Bromocriptine, a centrally acting dopamine D2-receptor agonist, was reported to regulate food intake and improve insulin sensitive and glucose tolerance in obese subject.

Aim: The objective of this study is to investigate the potential effect of bromocriptine on body weight and metabolic parameter as well as the inflammatory response in obese women.

Method: Out of 46 women enrolled in the study, 12 women did not complete study.

The remaining 34 patients divided into two groups Group I: Control group (N=16), this group advised only for dietary therapy plus life style modifications.

Group II: Bromocriptine group (N=18); The women of this group given 2.5mg bromocriptine at morning once daily for 12 weeks in addition dietary therapy plus life style modifications as in group I.Body weight (WT) and body mass index (BMI) and Fasting blood glucose level (FBG) , Lipid profile [total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C)] and inflammatory markers high sensitive C-reactive protein (hsCRP) and tumor necrosis factor alpha (TNF-α) were measured before and after 12 weeks of the treatment.

Results:Compared to baseline value, WT and BMI decreased significantly on both bromocriptine and control group but the change in WT and BMI did not significantly different between the two groups.

Bromocriptine treatment for 12 weeks significantly (P<0.05) improve FBG, TG and LDL-C compared to the base line value and alsothe reductions in FBG, TG and LDL-C were significantly (P<0.05) higher than that observed in control group.

Both hsCRP and TNF-α significantly (P<0.05) reduced by bromocriptine after 12 weeks compared to the baseline and the decrease in hsCRP was significantly different from that in the control group.

Conclusion: Bromocriptine effectively reduced fasting glucose, improved lipid profile and suppressed low grade inflammatory response on obese women.

Recommendation: Further clinical study on large sample size and longer duration is recommended to explore bromocriptine effects on health obese subject.